This page uses content from Wikipedia and is licensed under CC BY-SA.


LY-272,015 structure.png
Clinical data
Other namesLY-272,015; 1-[(3,4-Dimethoxyphenyl)methy]-2,3,4,9-tetrahydro-6-methyl-1H-pyrido[3,4-b]indole
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass336.426 g/mol g·mol−1
3D model (JSmol)

LY-272,015 is a beta-carboline derivative drug developed by Eli Lilly, which acts as a potent and selective antagonist at the serotonin 5-HT2B receptor. It has anti-hypertensive effects in animal models,[1][2] and is also used in research into the other functions of the 5-HT2B receptor.[3]


  1. ^ Watts SW, Fink GD (March 1999). "5-HT2B-receptor antagonist LY-272015 is antihypertensive in DOCA-salt-hypertensive rats". The American Journal of Physiology. 276 (3): H944-52. doi:10.1152/ajpheart.1999.276.3.H944. PMID 10070078.
  2. ^ Russell A, Banes A, Berlin H, Fink GD, Watts SW (October 2002). "5-Hydroxytryptamine(2B) receptor function is enhanced in the N(omega)-nitro-L-arginine hypertensive rat". The Journal of Pharmacology and Experimental Therapeutics. 303 (1): 179–87. doi:10.1124/jpet.102.037390. PMID 12235249.
  3. ^ Günther S, Maroteaux L, Schwarzacher SW (August 2006). "Endogenous 5-HT2B receptor activation regulates neonatal respiratory activity in vitro". Journal of Neurobiology. 66 (9): 949–61. doi:10.1002/neu.20253. PMID 16758492.